Citation | Study design | Participants | Treatment(s) | Context | Treatment effect |
---|---|---|---|---|---|
Healthy participants | |||||
Zuardi et al. (1993) [207] | DB (PC); BSD | I: 10; 23 y C: 10; 23 y | Oral 300 mg | Public speaking (90 min post-tx) | CBD sig. reduced SA post-public speaking. SA prior to, in anticipation of, and during speaking were unaffected. |
Crippa et al. (2004) [45] | DB (PC); BSD | I: 5 M; 30 ± 5 y C: 5 M; 30 ± 5 y | Oral 400 mg | Low stress | CBD sig. reduced SA 60 and 75 min post-tx. |
Bhattacharyya et al. (2010) [18] | DB (PC); WSD | 15 M; 27 ± 6 y | Oral 600 mg | Low stress | SA was unaffected 1, 2 and 3 h post-tx. |
Martin-Santos et al. (2012) [123] | DB (PC); WSD | 16 M; 26 ± 5 y | Oral 600 mg | Low stress | SA was unaffected 1, 2 and 3 h post-tx. |
Hindocha et al. (2015) [86] | DB (PC); WSD | 48; 22 y | Vaporised 16 mg | Low stress | SA was unaffected 2, 30, 60. 90 and 120 min post-tx. |
Zuardi et al. (2017) [208] | DB (PC); BSD | I: 12 (6 M); 23 ± 3 y I: 11 (5 M); 23 ± 3 y I: 12 (6 M); 23 ± 3 y C: 12 (6 M); 22 ± 2 y | I: Oral 100 mg I: Oral 300 mg I: Oral 900 mg | Public speaking (150 min post-tx) | 300 mg CBD sig. reduced SA compared to 900 mg CBD (but not placebo) during public speaking. SA prior to, in anticipation of, and post-speaking were not affected by any treatment. |
Linares et al. (2019) [116] | DB (PC); BSD | I: 15 M; 24 ± 3 y I: 15 M; 25 ± 3 y I: 12 M; 23 ± 3 y C: 15 M; 25 ± 4 y | I: Oral 150 mg I: Oral 300 mg I: Oral 600 mg | Public speaking (90 min post-tx) | 300 mg CBD (but not 150 or 600 mg) sig. reduced SA during public speaking. SA prior to, in anticipation of, and post-speaking were not affected by any treatment. |
Clinical populations | |||||
Crippa et al. (2011) [44] | DB (PC); WSD SAD Participants | 10 M; 24 ± 4 y | Oral 400 mg | Low stress | CBD sig. reduced SA 60, 75 and 140 min post-Tx. |
Bergamaschi et al. (2011) [15] | DB (PC); BSD SAD Participants | I: 12 (6 M); 23 ± 2 y C: 12 (6 M); 23 ± 2 y | Oral 600 mg | Public speaking (90 min Post-Tx) | CBD sig. reduced SA during public speaking. SA prior to, in anticipation of, and post-speaking were not affected. |
Hundal et al. (2017) [90] | DB (PC); BSD High Trait Paranoia | I: 16 (8 M); 26 ± 9 y C: 18 (8 M); 25 ± 8 y | Oral 600 mg | Virtual reality (130 min Post-Tx) | SA was unaffected. |
Masataka (2019) [124] | DB (PC); BSD SAD Participants | I: 17 (8 M); 18–19 y C: 20 (8 M); 18–19 y | Oral 300 mg·d-1 (28-days) | Low stress | CBD sig. reduced SA 4-weeks post-tx. |